Statin Treatment and Mortality in Bacterial Infections – A Systematic Review and Meta-Analysis by Björkhem-Bergman, Linda et al.
Statin Treatment and Mortality in Bacterial Infections – A
Systematic Review and Meta-Analysis
Linda Bjo ¨rkhem-Bergman
1*, Peter Bergman
2,3, Jan Andersson
3, Jonatan D. Lindh
1
1Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden, 2Division of
Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden, 3Division of Infectious
Diseases, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
Abstract
Background: Several studies have reported improved survival in severe bacterial infections among statin treated patients. In
addition, statins have been ascribed beneficial anti-inflammatory effects. The aim of this study was to evaluate the effect of
statin-treatment on mortality in patients with bacterial infections, by means of a systematic review and a meta-analysis.
Methodology and Principal Findings: Studies investigating the association between statin use and mortality in patients
with bacterial disease were identified in a systematic literature review and a meta-analysis was performed to calculate the
overall odds ratio of mortality in statin users. The literature search identified 947 citations from which 40 relevant studies
were extracted. In all, 15 studies comprising 113 910 patients were included in the final analysis. Statin use was associated
with a significantly (p,0.0001) reduced mortality in patients suffering from bacterial infections (OR 0.52, 95% CI 0.42–0.66).
However, all studies included were of observational design and funnel plot analyses indicated influence by a possible
publication bias (Egger’s bias test p,0.05). When a precision estimate test was used to adjust for publication bias the effect
of statin treatment was no longer significant, with an OR of 0.79 (95% CI 0.58–1.07).
Conclusion/Significance: According to the meta-analysis of observational studies presented here, patients on statin therapy
seem to have a better outcome in bacterial infections. However, the association did not reach statistical significance after
adjustment for apparent publication bias. Thus, there is a great need for randomised controlled trials investigating the
possible beneficial effect of statins in bacterial infections.
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Introduction
Statins (HMG-CoA reductase inhibitors) are today some of the
most prescribed drugs in the world due to their beneficial effects on
cardiovascular disease. During recent years statins have been
ascribed additional beneficial effects on the outcome of other
diseases, such as cancer and infections [1,2]. Some of these
‘‘pleiotropic effects’’ might be explained by a potential anti-
inflammatory effect of statins [3,4]. In the PRINCE-study
pravastatin treatment reduced the levels of C-reactive protein
(CRP) in a cholesterol independent way, although the clinical
significance of this reduction remains unresolved [5]. Beneficial
effects of statin treatment in transplanted patients have been
reported and suggest an immunomodulatory effect [6,7] although a
recent Cochrane review failed to show a significant reduction in all-
cause mortality among statin treated renal transplant patients [8].
A number of epidemiologic studies support that statin treatment
is associated with a better prognosis in severe bacterial infections
[1]. However, there is a lack of randomised controlled trials that
prospectively investigate the effect of statin treatment in patients
diagnosed with severe infections.
In a recent systematic review by Kopterides and Falagas [1] 22
original studies on the role of statins in infections were identified.
These studies yielded heterogeneous results and were not always
powered to provide precise quantitative estimates of the potential
statin effect. To provide a summarized estimate of the proposed
statin effect Tleyjeh et al performed a meta-analysis demonstrating
that statin use was associated with a beneficial effect in treating
and preventing infections [9]. However, meta-analyses of
observational studies are sensitive to influences by confounding
and other sources of bias and the result of such analyses should be
interpreted with great caution. Here, we present the results of a
new systematic review and meta-analysis, expanding on previous
findings by inclusion of novel studies and older studies that were
not included in the meta-analysis by Tleyjeh et al. In addition, we
have performed an in-depth analysis of potential bias sources,
providing quantitative estimates of their influence on the meta-
analysis results. Our primary objective was to summarize and
critically evaluate the current knowledge on statin treatment as a
therapeutic agent during bacterial infections. Studies investigating the
prophylactic effects of statins were excluded in our analysis.
However, to give a better over-view of all studies published in this
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literature search, i.e also the prophylactic studies excluded in the
meta-analysis.
Methods
Search strategy
The literature search was conducted in PubMed and Embase
(finished April 2010). Searches were not restricted to time or
language.
In PubMed the following terms for statins as MeSH or text
word (Hydroxymethylglutaryl-CoA Reductase Inhibitors OR
Hydroxymethylglutaryl-CoA Reductase Inhibitors [Pharmacolog-
ical Action] OR HMGCoA reductase inhibitors OR simvastatin
OR lovastatin OR pravastatin OR fluvastatin OR atorvastatin
OR cerivastatin OR rosuvastatin OR pitavastatin OR statins)
were combined with (bacteremia OR sepsis OR pneumonia OR
infections), as both MeSH or text word.
In Embase the following terms for statins (hydroxymethylglu-
taryl coenzyme a reductase inhibitor OR simvastatin OR
lovastatin OR pravastatin OR fluvastatin OR atorvastatin OR
cerivastatin OR rosuvastatin OR pitavastatin OR statins) were
combined with terms for bacterial infections (bacteremia OR
sepsis OR pneumonia OR bacterial infection) and terms for the
study types (prevention study OR pilot study OR observational
study OR experimental study OR controlled study OR compar-
ative study) all as Emtree preferred terminology.
In cases of missing data authors were contacted for additional
information or unpublished data.
Study selection criteria
The aim of the present investigation was not to study the
potential preventive effect of statins against infection but rather to
evaluate the influence of statin treatment on the disease progress
and prognosis in bacterial infection. In accordance with this
included studies had to meet the following criteria: (1) retrospective
or prospective studies investigating the outcome in bacterial
infections in statin treated versus non-statin treated patients (2) all
included patients had to have a bacterial infection such as
pneumonia, sepsis, bacteraemia or symptoms of a severe bacterial
infection. (3) All-cause mortality data or infectious mortality data
in statin treated versus non-statin treated subjects had to be
presented. If effect estimates adjusted for potential confounders
were not presented the authors were contacted with a request for
adjusted data. Statin use was defined as current statin use at time
of hospital admission. Studies addressing viral infections such as
HIV or CMV were excluded.
Data extraction
One reviewer (LBB) initially evaluated all the abstracts from the
literature search and extracted potentially relevant studies
addressing the association between statin exposure and the
outcome of bacterial infections. These studies were retrieved and
evaluated by two independent reviewers (LBB and PB). Studies
fulfilling the inclusion criteria of the meta-analysis were extracted
and summarized independently by the two reviewers (LBB and
PB). Recorded data included characteristics of the studies,
demographic data, and outcome in statin users and non-users
with severe infections. Any discrepancies were resolved by
consensus.
Statistical methods
The primary effect measure used in the meta-analysis was the
infectious mortality or odds ratio (OR) for in-hospital or all-cause
30 day mortality. If both all-cause and infectious mortality was
available, the latter was used as primary effect measure. When
available, ORs adjusted for potential confounders (age, sex, disease
severity, comorbidities, comedication etc.) were used. When
adjusted OR was not presented the authors were contacted for
additional information. If no adjusted OR-values could be
obtained the study was excluded from the main analysis.
Odds ratios from all included studies were pooled in a meta-
analysis weighting the individual studies according to their log-
transformed inverse variance. Homogeneity among studies was
tested by means of Cochran’s Q test and calculation of the
variation across studies attributable to heterogeneity rather than
chance (I
2). When substantial heterogeneity was demonstrated
(defined as a Cochran Q test p value ,0.1 or a I
2 value .25%) a
random-effects model was used to calculate the overall effect,
otherwise a fixed-effect model was used. In a secondary analysis,
we repeated the meta-analysis after addition of the studies where
only unadjusted odds ratios were available, excluded in the main
analysis.
Sensitivity analyses were performed to assess the influence of
various study characteristics on the observed statin effect. Both
studies with adjusted and studies with unadjusted odds ratios were
included in the sensitivity analyses. Firstly, the possible influence of
publication bias was graphically evaluated by means of a funnel
plot where log-transformed odds ratios were plotted against
standard errors. The presence of funnel plot asymmetries was
formally analysed using Egger’s bias test. In addition, the
precision-effect test (PET) was used to calculate an overall OR
adjusted for observed funnel plot asymmetries indicative of
publication bias [10]. In this test, the normalized effect estimate
(OR divided by its standard error) is regressed on the inverse
standard error of the effect, whereby the slope of the regression
lines offers a logarithmised estimate of the pooled OR adjusted for
any observed association between effect size and study precision.
Secondly, the influence of a range of study-level and aggregated
individual-level parameters on the observed statin effect was
investigated by means of meta-regressions. In these analyses, the
odds ratio from each study was regressed on the potential
confounders in univariable and multivariable weighted linear
regressions weighted according to the inverse standard error and
the residual between-trial variance. Independent variables includ-
ed in the multivariable analysis were chosen by means of backward
selection with successive exclusion of the least significant variable
until only significant predictors of study outcome remained in the
model. In total, twelve dichotomous and four continuous
parameters were investigated in these analyses. The dicothomous
parameters (coded as 1 for yes and 0 for no) were prospective study
design, case-control design (as opposed to cohort design) Asian,
European, or North-American setting (Australian studies were
coded 0 for each of these; no African studies were identified),
industry-sponsored or industry-independent studies (studies with
undisclosed financing were coded 0 for both), infection-related
mortality as outcome (as opposed to all-cause mortality), in-
hospital mortality (as opposed to e.g. 30-day mortality), infection-
related mortality as outcome (as opposed to all-cause mortality),
statistical adjustment for potential confounders performed, and
pneumonia or sepsis/bacteremia as requirement for inclusion.
Continuous variables were the impact factor of the journal where
the study was published, standard error of the association measure
(OR), patient age (per year), and the proportion of included
patients being male (ranging from 0 in a study with only female
subjects to 1 in an exclusively-male study).
Thirdly, the potential influence of unknown confounders
(residual confounding) was investigated by means of a rule-out
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the influence of a hypothetical confounder and determines what
characteristics this confounder must have in order to fully account
for the observed association between statin use and mortality. The
hypothetical confounder is characterised by its association to statin
use (OREC, odds ratio of exposure to the confounder in statin non-
users vs statin users) and its association to the outcome (RRCO,
relative risk of outcome in individuals exposed to the confounder
vs non-exposed). For this analysis, the absolute risk in the pooled
control group was used for conversion of odds ratio to relative risk.
Separate analyses were performed to demonstrate what levels of
OREC and RRCO that would be required to fully explain the
observed association between statins and mortality before and
after adjustment for publication bias as described above.
Finally, the overall effect of adjusting for potential individual-
level confounders was investigated by calculating the mean ratio of
adjusted odds ratio over unadjusted odds ratio in the subset of
studies where both effect measures were available.
In all analyses except the Cochran’s Q test, results associated
with p-values ,0.05 (two-sided test) were considered statistically
significant. The statistical analyses were performed using StatsDir-
ect statistical software version 2.7.2 (StatsDirect, Sale, Cheshire,
UK).
Results
Identification of studies
The literature search resulted in 947 citations, 39 of which
addressed statin-treatment and the outcome of bacterial infections
(Figure 1). This was in accordance with the literature identified in
earlier systematic reviews [1,9] but with addition of several novel
studies. One article comprised both a case-control study and a
cohort study [12] and was therefore divided into two studies. We
defined the studies as either prophylactic (studies of association
between statin use and risk of acquiring infection) or therapeutic
(studies of association between statin use and outcome of manifest
infection).
Evaluation of the 40 studies showed that 21 studies
[12,13,14,15,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33]
were investigating the prophylactic effect of statin treatment
on infections and 19 investigating the therapeutic effect
[12,16,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50]. All
the prophylactic studies were excluded from the meta-analysis
since the patients did not have a bacterial infection at baseline in
these studies. One study investigated the therapeutic effect of statins
in patients with multiple organ dysfunction failure (MODS) but
since the MODS was due not only to sepsis or pneumonia but also
to cardiac causes or stroke this study was excluded [47]. One study
investigated the therapeutic effect of statins in patients with fever
.38uC at admission to hospital but since there was documentation
of bacterial infections in only 16% of the patients this study was also
excluded [36].
One study did not distinguish between influenza and/or
bacterial pneumonia and since the cause of death in influenza is
often due to secondary bacterial infections this study was included
[43]. In the study by Donnino and co-workers [37] all patients had
a diagnosis consistent with infections (pneumonia, sepsis, pyelo-
nephritis) or symptoms of severe infections (altered mental status,
shortness of breath etc). Since the majority of the patients were
assumed to suffer from a bacterial infection, and that this was the
cause of death, this study was included.
Two of the therapeutic studies were excluded since only
unadjusted OR values for mortality in bacterial infections were
available [34,42]. In the study by Frost et al the statin-exposed
group (n=3578) was subdivided into statin user with a low dose
(n=238) and a moderate dose (n=3340). Only the data from the
statin users with a moderate dose ($4 mg/day) was included [12].
Results from the included studies (Table S1)
Fifteen studies comprising 113 910 patients (8611 statin-users
and 105 299 non statin-users) fulfilled the inclusion criteria for the
meta-analysis and were included in the final analysis (Table S1).
Table S1 presents the characteristics of the studies included
in the meta-analysis. All studies were published between 2001
and 2009 and the mean age in the studies varied between 48–
75 years. In 5 of the 15 included studies the type of statins used
was described. Several different types of statins were used in all
these studies, although simvastatin was usually the most
common one. In two studies estimates of infection-related
mortality could be obtained [12,50]. The factors adjusted for in the
different studies included age [12,16,35,38,41,43,45,46,48,49], sex
[12,16,37,38,41,43,45,46,48,49], co-morbidity [35,37,38,41,44,46,
48,49], severity of illness [16,35,37,38,44,46,48,49], co-medication
[35,41,43,45,46,48,49], marital status [43,45,49], smoking [35,41,
46], alcohol-related conditions [44,48,49], characteristic of infections
[38,48], quality of care [37,38,41,44,48,49] and ethnicity [43,45].
Statin-users in all studies were on current statin treatment at the
time of hospital admission and in five studies all patients defined as
statin users had to be on statin treatment during the whole in-
hospital stay [37,39,40,41,50]. In 13 studies the time exposure for
statin treatment before hospital admission was unknown. In the
case-control study of Frost et al statin-users had been taking statins
for at least 3 months [12] and in the study by Yang et al statin
exposure was at least 1 month in all statin users [50].
In the articles addressing ‘‘bacteraemia’’ this entity was defined
as the presence of at least one positive blood culture of a clinically
relevant pathogen. In three of the four bacteraemia studies,
patients should also have symptoms of infection. In the articles
addressing ‘‘sepsis’’ this diagnosis was defined according to ICD-9
criteria for sepsis and/or the sepsis criteria proposed by American
Collage of Chest Physicians and the Society of Critical Care
Medicin (ACCP-SCCM) [51]. The patients in the sepsis studies
generally had a more severe disease compared to the patients in
the bacteraemia studies, and the mean mortality in the sepsis
studies was 34% compared to 21% in the bacteraemia studies. The
Figure 1. Flow diagram showing the number of citations
identified, retrieved and included in final analysis.
doi:10.1371/journal.pone.0010702.g001
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studies addressing any infection it was 6%.
Results from prophylactic studies (Table S2)
Many of the originally selected studies were investigating the
prophylactic effects of statins on infection and thus did not meet the
inclusion criteria of our meta-analysis. However some were of
high-quality and with potentially valuable results and therefore we
chose to present data from all excluded studies in a separate table
(Table S2). The article by Frost et al comprised two studies, where
the case-control study were included in the meta-analysis
(presented in Table S1) and the cohort study was excluded and
therefore presented in Table S2 [12].
We identified 9 studies investigated the association between
statin use and risk of developing pneumonia or respiratory
infections [12,17,19,23,24,27,29,30,33], 5 showing some beneficial
effect and 4 revealing no significant effect.
In the large cohort study by Hackam et al and in the prospective
cohort study by Gupta et al a significantly decreased risk of sepsis
and fatal sepsis in statin users could be observed [20,21].
In the two small RCTs by Tseng et al and Montaner et al there
was no convincing association of statin use and a beneficial
outcome on infection post subarachnoidal haemorrhage or stroke
but the limited number of patients included makes the results less
reliable [26,32].
Five studies investigated the association between statin treat-
ment and post operative infections after cardiac surgery
[14,25,31], herniorraphy [22] or any elective surgery [15]. Only
one of these studies showed a marginally favourable effect of statin
and the over-all impression from these studies is that statins have
no convincing prophylactic effect on post-operative infections.
Of all the 40 studies described here (table S1 and S2), 22 studies
showed a significantly favourable association between statin
therapy and the outcome of bacterial infection, 16 showed no
significant association and 2 showed unfavourable association with
statin exposure.
Meta-analysis of therapeutic studies
There was evidence of a substantial between-studies heteroge-
neity in the overall meta-analysis (Cochran Q test p=0.001,
I
2=60%) and consequently a random-effects model was used in
the meta-analysis. A forest plot of the analysis of all 15 included
studies is presented in figure 2. Statin use was associated with a
significantly (p,0.0001) reduced mortality in patients suffering
from bacterial infections (OR 0.52, 95% confidence interval (CI)
0.42–0.66). Inclusion of two additional studies where only
unadjusted values were available [34,42] had no influence on
the outcome of the meta-analysis (OR 0.53, 95% CI 0.43–0.65).
Sensitivity analyses
A funnel plot of the studies included in the overall analysis is
presented in figure 3. From this plot it is evident that studies with a
lower precision (larger standard error) were more likely to present
large statin effects, a pattern indicative of publication bias. This
was confirmed by a significant Egger’s bias test (p,0.05). When
the precision estimate test was used to adjust for publication bias,
the overall OR was altered to 0.79 (95% CI 0.58–1.07).
The outcome of the univariable and multivariable meta-
regressions are presented in table S3. In the univariable analyses,
the only factors significantly associated with study outcome was the
prospective study design and industry sponsorship. Since the
number of potential confounders addressed was too large for the
initial multivariable model, age, impact factor, case-control design,
and European/North-American origin were excluded from the
multivariable analysis. These factors exhibited high levels of
correlation with other included variables and excluding them
effectively reduced the co-linearity of the model. After exclusion of
non-significant predictors, the final model included seven potential
confounders: prospective study design, adjustment for potential
confounders, industry-independent funding, Asian setting, in-
hospital mortality and infection-related mortality as outcome,
and standard error of the effect estimate. A larger standard error,
adjustment for confounding and the use of infection-related
mortality as study outcome were associated with lower odds ratios
while the remaining four factors were associated with higher odds
ratios.
The results of the residual confounding analysis are presented in
figure 4. Panel A refers to a confounder with a prevalence of 0.20
and at this prevalence level even a very strong confounder causing
a ten-fold increased mortality risk would have to be severely
imbalanced between statin users and non users (OREC=3.9) in
order to fully account for the observed unadjusted OR of 0.52.
Adjusting for apparent publication bias (adjusted OR=0.79)
reduced the demands on the hypothetical confounder. Neverthe-
less, a confounder that increase the mortality risk a full four times
would still have to be distinctly imbalanced (OREC=2.3) in order
to explain the adjusted statin effect. For a very common
confounder with a prevalence of 0.50, weaker associations with
statin use and/or mortality would be sufficient to explain the
observed association between statin use and mortality (figure 4,
panel B). However, at this prevalence level the confounder would
still have to be both quite imbalanced and increase the mortality
risk several fold in order to account for the observed OR, even
after taking publication bias into account.
When comparing adjusted vs unadjusted ORs within studies,
the former were on average 6% lower, indicating a modest
influence of the individual-level confounders addressed in these
studies.
Discussion
The findings in this systemic review and meta-analysis show a
possible association between statin treatment and reduced
mortality rate after having been diagnosed with bacterial
infections. In addition, the combined results from the prophylactic
(excluded) studies presented in Table S2 imply that a possible
beneficial prophylactic effect of statins in prevention of sepsis and
pneumonia cannot be ruled out. In contrast, there appears to be
weak evidence for statins in the prevention of post-operative
infections (Table S2).
According to the meta-analysis presented here, statin use is
associated with an almost 50% lower odds of death during
bacterial infections. Although this estimate is mainly based on data
adjusted for potential confounders such as differences in age, sex,
disease severity and comorbidities, the sensitivity analysis clearly
indicates that the result may still be influenced by other sources of
bias. One such factor is likely to be publication bias due to selective
publishing of results in favour of a pronounced statin effect. Unlike
Tleyjeh and co-workers [9], we were able to demonstrate a
significant influence by publication bias (Egger’s bias test p,0.05).
Notably, the previous meta-analysis included both prophylactic
and therapeutic studies.
Based on our finding, we further attempted to adjust our results
for the observed signs of publication bias, discovering that
approximately half the observed statin effect could be attributable
to publication bias.
To identify other factors of potential importance for the
observed statin effect, we investigated the association between a
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studies. Factors that were predictive of a smaller statin effect in a
multivariable analysis were prospective study design, industry-
independent funding, Asian study setting and a short follow-up
time (in-hospital mortality). The mechanisms underlying these
associations are not clear, but the weaker association seen in
studies with a prospective study design may indicate additional
bias sources in studies with retrospective design, leading to inflated
association strength estimates in these studies. Similarily, industry
sponsorship is a factor known to influence the outcome of clinical
trials, with a bias in favour of products marketed by the supporting
organisation [52]. The lower odds ratio associated with in-hospital
mortality rather than 30-day mortality could reflect a protective
effect of statins most pronounced after the acute phase of infection,
but the limited information does not allow any definitive
conclusions regarding the time-course of the proposed statin
effect. Theoretically, the reduced OR (closer to null) in the Asian
studies could represent an influence of pharmacogenetic or
environmental factors, but until more data from Asian patient
populations are available, this association should be interpreted
with great caution. Factors predictive of a stronger association
between statin use and mortality in patients with infection were the
use of infection-related mortality rather than all-cause mortality as
clinical endpoint and the application of statistical adjustment for
potential patient-level confounders. The former factor could speak
in favour of a causal relationship between statin exposure and the
clinical course of manifest infection, since such a protective effect
may be most evident on infection-related mortality, undiluted by
other causes of death. The stronger association in studies adjusting
for potential confounders may seem surprising if adjustment is
Figure 2. Forest plot of all included studies in the meta-analysis. Estimated OR in statin-users vs non-users for infectious/30-day/in-hospital
mortality among patients diagnosed with a severe bacterial infection. Brackets denote 95% confidence intervals.
doi:10.1371/journal.pone.0010702.g002
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on confounding. However, confounding factors can also work in
the opposite direction by attenuating true associations. In this
situation, the adjustment is expected to strengthen the association
as seen in the sensitivity analysis. The association between
adjustment and a lower OR is further supported by the within-
studies analysis, where adjusted ORs on average were 6% lower
than their unadjusted counterparts.
All the included studies were of observational design, and the
patients were non-randomly assigned to statin therapy. Since some
factors underlying the decision to treat a patient with statins are
likely to be unknown or unavailable for analysis, it is not possible
to fully adjust the results for confounding. For example, the results
from this meta-analysis could be influenced by the ‘‘healthy-users’’
effect, i.e. a situation where statin-users systematically care more
for their health, have a higher socioeconomic status and other
characteristics making them more likely to survive a severe
infection. This is highlighted in an interesting article of Dormuth
et al where statin adherence is reported to be associated with a
significant decreased risk of developing diseases unrelated to the
known biological effect of statins as well as a decreased rate of
having accidents [53]. In addition, statin adherence was associated
Figure 3. Funnel plot of the association between the estimated effect size and its standard error in individual studies. The stronger
association between statin use and mortality seen in studies with lower precision (large standard error) is suggestive of publication bias with selective
publication of studies with favourable results.
doi:10.1371/journal.pone.0010702.g003
Figure 4. Modelled influence of a hypothetical dichotomous confounder present in 20% (panel A) and 50% (panel B) of the study
population, unaccounted for in the adjustments already performed in the individual studies. The graphs indicate what combinations of
OREC and RRCO that would be necessary for the confounder to fully account for the observed association between statin use and mortality before
(OR=0.52) and after (OR=0.79) adjustment for publication bias. Abbreviations: OREC, odds ratio of exposure to the confounder in statin non-users vs
statin users; RRCO, relative risk of mortality in individuals exposed to the confounder vs non-exposed.
doi:10.1371/journal.pone.0010702.g004
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[53]. On the other hand, patients taking statins most probably
have a history of cardiovascular disease or risk factors for
cardiovascular disease and could therefore be expected to have a
poorer prognosis associated with severe infections putting a strain
on the cardiovascular system.
To investigate the potential influence of uncontrolled con-
founding on the results, we calculated the magnitude of association
with statin use and mortality that a hypothetical confounder would
need to fully account for the apparent statin effect. This analysis
showed that only a very strong confounder would be able to
explain the statin association seen in the main analysis. After
adjustment for publication bias, a more modest confounder could
be sufficient. However, a highly prevalent confounding factor that
doubles the mortality risk would still have to be quite imbalanced
between the statin non-users and the statin users (OR of exposure
to confounder approaching 4) while a more balanced confounder
(OR=2) would have to increase mortality by 4-fold in order to
account for the observed association between statins and mortality.
Hence, it seems unlikely that the observed association is entirely
due to confounding and that the statins are completely devoid of a
causal influence on mortality in severe infection. In addition, it
should be noticed that the confounding model employed stipulates
a cofounder entirely independent of the factors adjusted for in the
individual studies. If, as may often be the case, the unknown
confounder is correlated to the confounders already adjusted for,
its impact could be much smaller than the model indicates.
The reduced mortality in severe bacterial infections might be
explained by the reported anti-inflammatory and immunomodu-
latory effects of statins [3,4]. By inhibiting the HMGCoA-
reductase, statins inhibit the synthesis of isoprenoid units,
necessary for the activity of a number of proteins, such as the
GTP-binding protein Rho. Statins may thus affect transcription
factors such as NFkB and AP-1, leading to a decreased synthesis of
pro-inflammatory cytokines such as IL-1 and IL-6 [4]. Moreover,
statins have also been reported to induce caspase-dependent
apoptosis in smooth muscle cells [4], which leads to less
inflammation by avoiding the necrotic cell-death pathway. Despite
the multitude of possible immunomodulatory actions exerted by
statins the protective immune response against pathogens appear
to remain intact. Thus, it could be speculated that statins
strengthen immunity to pathogens while simultaneously dampen
the inflammatory response connected to bacterial infections and
sepsis. Interestingly, in vitro experiments have suggested that statins
specifically inhibit proinflammatory Th1- and Th17-cells shifting
the T-cell population towards an anti-inflammatory profile
dominated by IL-10 producing T-regulatory cells [54,55].
However, the in vivo mechanism behind the reported anti-
inflammatory effects of statins is not fully elucidated. Notably,
the concentrations used in most in vitro experiments are up to 1000
times higher than what is detected in human plasma during statin
treatment [54,55,56].
It has been reported that both the lipid-lowering and anti-
inflammatory effect of statins differ between individual substances
in the drug class [57,58]. It would have been of great interest to
make a subgroup analysis comparing different statins with regard
to their effect on mortality. However, this was not possible since all
studies were of observational design, lacking allocation to a specific
type of statin. Moreover, information on the individual statins used
was only provided in 5 of the 15 studies.
Even though the results indicate that statins may improve the
prognosis in bacterial infection, the magnitude of this effect is not
easily estimated due to potential bias. However, we can conclude
that statin treatment does not appear to be associated with any
unfavourable outcome on mortality in severe bacterial infections.
To fully compensate for different bias-effects inherent to
observational studies, large randomised controlled trials (RCT)
testing the hypothesis that statin treatment has beneficial effects on
the outcome of infections are highly warranted. In fact, several
such studies are ongoing according to www.clinicaltrials.gov and
an additional RCT will commence at our center during 2010 at
Karolinska University Hospital Huddinge, Sweden (personal
communication: Dr Christer Lidman and Prof Jan Andersson).
In conclusion, we believe that our meta-analysis provide a solid
rationale for future interventional randomized controlled trials
investigating the hypothesis that statins improve the clinical
outcome of infectious diseases.
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